HER2-positive Breast Cancer
Conditions
Keywords
Neoadjuvant Therapy, Pyrotinib, Trastuzumab, Pathological Complete Response
Brief summary
This is a single-arm, multicenter clinical study designed to evaluate the efficacy and safety of pyrotinib and trastuzumab combined with pegylated liposomal doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel for injection albumin bound as neoadjuvant therapy in patients with early HER2-positive breast cancer. Eligible patients will receive 8 cycles of neoadjuvant treatment. Pyrotinib will be administered orally once daily, and trastuzumab will be administered intravenously every 3 weeks. During the first 4 cycles, patients will receive pegylated liposomal doxorubicin hydrochloride and cyclophosphamide. During the subsequent 4 cycles, patients will receive paclitaxel for injection albumin bound. The primary outcome is total pathological complete response rate. Secondary outcomes include breast pathological complete response rate, lymph node pathological complete response rate, objective response rate, event-free survival, distant disease-free survival, overall survival, and safety.
Interventions
Pyrotinib maleate will be administered orally at 400 mg once daily from Day 1 of Cycle 1. It should be taken within 30 minutes after breakfast and continued throughout the neoadjuvant treatment period.
Trastuzumab will be administered intravenously at a loading dose of 8 mg/kg on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of each subsequent 3-week cycle during neoadjuvant treatment.
DRUGpegylated liposomal doxorubicin hydrochloride
Pegylated liposomal doxorubicin hydrochloride will be administered intravenously at 35 mg/m² on Day 1 of each 3-week cycle for the first 4 cycles of neoadjuvant treatment.
DRUGCyclophosphamide
Cyclophosphamide will be administered intravenously at 600 mg/m² on Day 1 of each 3-week cycle for the first 4 cycles of neoadjuvant treatment in combination with pegylated liposomal doxorubicin hydrochloride, pyrotinib, and trastuzumab.
DRUGPaclitaxel for Injection Albumin Bound
Paclitaxel for injection albumin bound will be administered intravenously at 230-260 mg/m² on Day 1 of each 3-week cycle for the subsequent 4 cycles of neoadjuvant treatment in combination with pyrotinib and trastuzumab.
Sponsors
Hebei Medical University Fourth Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
All enrolled participants will receive the same single-arm neoadjuvant treatment regimen consisting of pyrotinib and trastuzumab combined with pegylated liposomal doxorubicin hydrochloride and cyclophosphamide for 4 cycles, followed by paclitaxel for injection albumin bound combined with pyrotinib and trastuzumab for 4 cycles.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Female patients aged 18 to 65 years. * Patients with previously untreated invasive breast cancer confirmed by pathological examination. * HER2-positive breast cancer, defined as immunohistochemistry (IHC) 3+ or IHC 2+ with HER2 gene amplification confirmed by in situ hybridization (ISH), regardless of hormone receptor status. * Clinical stage T2N0-3M0 or any T/N1-N3M0 according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system. * At least one measurable lesion according to RECIST version 1.1. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate organ function, meeting all of the following criteria: * Hemoglobin ≥100 g/L. * Absolute neutrophil count ≥1.5 × 10\^9/L. * Platelet count ≥100 × 10\^9/L. * Total bilirubin ≤1 × upper limit of normal (ULN). * Alanine aminotransferase and aspartate aminotransferase ≤1.5 × ULN. * Alkaline phosphatase ≤2.5 × ULN. * Blood urea nitrogen and serum creatinine ≤1.5 × ULN. * Left ventricular ejection fraction ≥55% by echocardiography. * Women of childbearing potential must have a negative serum pregnancy test within 7 days before enrollment and agree to use appropriate contraception during the study and for 8 weeks after the last dose of study treatment. * Patients must voluntarily participate in the study, sign the informed consent form, have good compliance, and be willing to cooperate with follow-up.
Exclusion criteria
* Prior receipt of any anti-tumor therapy, including chemotherapy, radiotherapy, molecular targeted therapy, or endocrine therapy. * Concurrent receipt of any other anti-tumor therapy. * Bilateral breast cancer, inflammatory breast cancer, or occult breast cancer. * Stage IV breast cancer. * Breast cancer not confirmed by pathological examination. * History of other malignancies within 5 years, except cured carcinoma in situ of the cervix. * Severe dysfunction of major organs, including the heart, liver, or kidney. * Inability to swallow, chronic diarrhea, intestinal obstruction, or other factors that may affect drug administration or absorption. * Participation in another drug clinical trial within 4 weeks before enrollment. * Known history of allergy to any component of the study treatment. * History of immunodeficiency, including positive HIV test, hepatitis C virus infection, active hepatitis B virus infection, other acquired or congenital immunodeficiency diseases, or history of organ transplantation. * History of any cardiac disease, including clinically significant arrhythmia requiring medication, myocardial infarction, heart failure, or any other cardiac disease judged by the investigator to make the patient unsuitable for this study. * Pregnant or breastfeeding women, women of childbearing potential with a positive baseline pregnancy test, or women of childbearing potential unwilling to use effective contraception throughout the study. * Serious concomitant diseases that, in the investigator's judgment, may compromise patient safety or affect completion of the study, including but not limited to uncontrolled severe hypertension, severe diabetes mellitus, or active infection. * Clear history of neurological or psychiatric disorders, including epilepsy or dementia. * Any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total Pathological Complete Response Rate | At the time of surgery after completion of neoadjuvant therapy, approximately 24 weeks after treatment initiation | Total pathological complete response is defined as the absence of residual invasive cancer in both the breast and axillary lymph nodes after neoadjuvant therapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Secondary Outcome Measure | At the time of surgery after completion of neoadjuvant therapy, approximately 24 weeks after treatment initiation | Breast pathological complete response is defined as the absence of residual invasive cancer in the breast after neoadjuvant therapy. |
| Lymph Node Pathological Complete Response Rate | At the time of surgery after completion of neoadjuvant therapy, approximately 24 weeks after treatment initiation | Lymph node pathological complete response is defined as the absence of residual invasive cancer in axillary lymph nodes after neoadjuvant therapy. |
| Objective Response Rate | From baseline to completion of neoadjuvant therapy, approximately 24 weeks | Objective response rate is defined as the proportion of participants who achieve complete response or partial response according to RECIST version 1.1 during neoadjuvant therapy. |
| Event-Free Survival | From enrollment to the first documented event or death, assessed up to 3 years | Event-free survival is defined as the time from enrollment to disease progression, recurrence, distant metastasis, second primary malignancy, or death from any cause, whichever occurs first. |
| Distant Disease-Free Survival | From enrollment to distant metastasis or death, assessed up to 3 years | Distant disease-free survival is defined as the time from enrollment to the first occurrence of distant metastasis or death from any cause, whichever occurs first. |
| Overall Survival | From enrollment to death from any cause, assessed up to 3 years | Overall survival is defined as the time from enrollment to death from any cause. Participants who are alive will be censored at the date of last follow-up. |
| Number of Participants With Adverse Events | From the first dose of study treatment to 30 days after the last dose of neoadjuvant treatment | Safety will be assessed by the incidence and severity of adverse events, graded according to NCI CTCAE version 5.0. |
Countries
China
Contacts
CONTACTZhenchuan Song, MD
CONTACTLina Zhang, MD
PRINCIPAL_INVESTIGATORZhenchuan Song
Hebei Medical University Fourth Hospital
Outcome results
None listed